Date: April 27-29, 2003
Location: Los Angeles, CA
The content presented here was prepared by independent authors under the editorial supervision of OncoEd and is not endorsed or sanctioned by the Development of Therapeutic Cancer Vaccines 2003 Meeting.
Conference Summaries
Conference Overview
The John Wayne Cancer Institute, the Association of Biologics and the Royal Society of Medicine sponsored a meeting in Los Angeles on April 27-29, 2003 concerning recent advances in the development of therapeutic cancer vaccines. This meeting was a thorough discussion of the current status and problems related to the development of therapeutic cancer vaccines.
Vaccines for Melanoma
During the Development of Therapeutic Cancer Vaccines conference held in Los Angeles, April 27-29, 2003, 4 vaccines for the treatment of melanoma were reviewed: Canvaxin™, Melacine®, MAGE-3.A1, and CD34+ dendritic cell vaccine.
Vaccines to Prevent and Treat HPV Associated Cervical Cancer
During the Development of Therapeutic Cancer Vaccines conference held in Los Angeles, April 27-29, 2003, recent advances in the development of vaccines to prevent and treat human papilloma virus (HPV) associated cervical cancer.
Dendritic Cell Vaccines
Dendritic cell vaccines were reviewed during the Development of Therapeutic Cancer Vaccines conference held in Los Angeles, April 27-29, 2003.
Hepatitis C Vaccines to Prevent Liver Cancer
Recent advances in the development of a Hepatitis C vaccine to prevent liver cancer were reviewed in the Therapeutic Cancer Vaccines conference held in Los Angeles April 27-29, 2003.
Patient Home
2009 Coverage
